PROTEOFORM SCIENTIFIC IS NOW ALLUMIQS CORPORATION. NEW NAME, EXPANDED OMICS SOLUTIONS.
  • Kent MacLean
    Chief Executive Officer

    A senior business development leader and visionary, Kent joined Allumiqs (formerly Proteoform Scientific) in 2018 to fully commercialize the company and lead strategic growth initiatives.

    Kent brings more than 30 years of global experience in finance, operations, and business development to the company. With in-depth knowledge and hands-on experience in both start-up and high-growth organizations in Canada, the United States, Caribbean, and Latin America, Kent has a proven track record in accelerated business achievements.

    Kent focuses on creating highly effective teams, expanding international markets, developing and nurturing key profitable business networks, and securing long-term client and partner relationships built on trust, which all contribute to successful business ventures.

  • Hugo Gagnon, Ph.D.
    Chief Scientific Officer

    Hugo became the Chief Scientific Officer when Allumiqs was created in early 2022. Previously, he served as the CEO and co-founder of PhenoSwitch Bioscience, which was acquired by Proteoform Scientific to create Allumiqs.

    During his Ph.D Hugo used mass spectrometry through different collaborations and core facility services to answer biological questions. He quickly learned that access to mass spectrometry was far from being simple and necessitates a considerable resource investment to obtain desirable results. Thus, PhenoSwitch Bioscience was founded, with a team of expert scientists, to address this specific need. Hugo studied at Université de Sherbrooke, where he earned a B.Sc. in biochemistry, M.Sc. in Pharmacology, and a Ph.D. in biochemistry.

    Hugo has been the driving force behind the innovative LC-MS/MS services offerings and high-quality reputation the company has developed within the biotech, omics, and mass spec industries.

  • Erin Cluney
    Global Business Development Manager

    Erin is our Global Business Development Manager. With a successful track record of key account management and sales in the life sciences sector since 2002, Erin leads Allumiqs’ customer-focused initiatives and develops and nurtures distribution channel partner relationships. Before joining our team in 2020, Erin worked in the pharmaceutical industry, holding roles with Janssen, Aspen Pharmacare, Boehringer Ingelheim, and GlaxoSmithKlein. She gained experience across multiple disease areas including oncology, cardiology, and endocrinology while building an excellent knowledge base and clinical aptitude, participating in product launches, and facilitating customer training

  • Andrea Young
    Manager, Marketing Communications

    Andrea has deep strategic and tactical marketing communication experience and sales enablement expertise in biotech and other emerging growth industries. Andrea joined Allumiqs’ predecessor company Proteoform Scientific in 2019 and previously spent 10+ years in the medical device industry. She is a results-oriented marcomm professional with both implementation and strategy development experience across a range of industries and dynamic working environments including life sciences, software development, telecommunications, not-for-profit, and professional services. She brings a consultative approach to shaping complex and technical details into digestible, relevant messages which supports Allumiqs’ business development and sales initiatives and strategies, as well as corporate and investor communications.

Board of Directors

  • Peter Hickey
    Co-founder & Chairman of the Board

    With over 18 years of experience leading globally-focused technology companies, Peter has worked with a number of large-scale clients including global, publicly traded firms and government organizations as well as smaller, privately-held companies. He was the CEO of Adaptiiv, co-founder of Oris4, and former CEO of Coemergence and director of a Hong Kong-based financial services firm.

  • Alan Doucette, Ph.D.
    Co-founder, Scientific Advisor & Director

    Alan Doucette is internationally recognized as a leader in proteomics front-end sample preparation, particularly as it applies to the analysis of intact proteins by top-down MS.
    He is credited with 35 peer-reviewed publications in the field of proteomics and analytical mass spectrometry and has made over 100 presentations at national and international scientific research conferences. He also has three patents and two license agreements for product commercialization. Since 2004, Alan has and continues to serve as a Professor of Chemistry at Dalhousie University. His program focuses on the development of advanced innovative technologies to improve advanced proteome characterization by mass spectrometry (MS).

  • Neil Smith
    Director

    Neil is an experienced surgeon and business leader with a demonstrated history in the healthcare industry. He has worked in both the private and public sector as a board chairman and executive chairman of a publicly traded company. Neil also has experience in transitioning companies from the private to public markets as well as raising capital, particularly for early stage start-ups in the biotech and life sciences space.

  • Kent MacLean
    Director & CEO

    A senior business development leader and visionary, Kent joined Allumiqs (formerly Proteoform Scientific) in 2018 to fully commercialize the company and lead strategic growth initiatives.

    Kent brings more than 30 years of global experience in finance, operations, and business development to the company. With in-depth knowledge and hands-on experience in both start-up and high-growth organizations in Canada, the United States, Caribbean, and Latin America, Kent has a proven track record in accelerated business achievements.

    Kent focuses on creating highly effective teams, expanding international markets, developing and nurturing key profitable business networks, and securing long-term client and partner relationships built on trust, which all contribute to successful business ventures.

  • Hugo Gagnon, Ph.D.
    Director & CSO

    Hugo became the Chief Scientific Officer when Allumiqs was created in early 2022. Previously, he served as the CEO and co-founder of PhenoSwitch Bioscience, which was acquired by Proteoform Scientific to create Allumiqs.

    During his Ph.D Hugo used mass spectrometry through different collaborations and core facility services to answer biological questions. He quickly learned that access to mass spectrometry was far from being simple and necessitates a considerable resource investment to obtain desirable results. Thus, PhenoSwitch Bioscience was founded, with a team of expert scientists, to address this specific need. Hugo studied at Université de Sherbrooke, where he earned a B.Sc. in biochemistry, M.Sc. in Pharmacology, and a Ph.D. in biochemistry.

    Hugo has been the driving force behind the innovative LC-MS/MS services offerings and high-quality reputation the company has developed within the biotech, omics, and mass spec industries.